Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer (Q80529955)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17592827%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

title

Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17592827%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

1 reference

1 reference

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17592827%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Louis Preston Garrison

1

object named as

Louis P Garrison

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17592827%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

6

Edith A Perez

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17592827%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

author name string

Deborah Lubeck

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17592827%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Deepa Lalla

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17592827%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Virginia Paton

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17592827%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

publication date

1 August 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17592827%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17592827%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

volume

110

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17592827%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17592827%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

page(s)

489-498

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17592827%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

cites work

Cancer statistics, 2006

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22806

7 January 2021

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22806

7 January 2021

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22806

7 January 2021

Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22806

7 January 2021

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22806

7 January 2021

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22806

7 January 2021

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22806

7 January 2021

Sequence of radiotherapy with tamoxifen in conservatively managed breast cancer does not affect local relapse rates

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22806

7 January 2021

Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, With or Without Trastuzumab As Adjuvant Therapy in Node-Positive, Human Epidermal Growth Factor Receptor 2–Overexpressing Bre

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22806

7 January 2021

A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22806

7 January 2021

Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22806

7 January 2021

The cost-effectiveness issue of adjuvant trastuzumab in early breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22806

7 January 2021

Topical imiquimod to treat recurrent breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22806

7 January 2021

Induction of tolerance in autoimmune diseases rather than cure of cancer by interleukin-2 therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22806

7 January 2021

An economic evaluation of Herceptin in adjuvant setting: the Breast Cancer International Research Group 006 trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22806

7 January 2021

Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22806

7 January 2021

Cost of illness associated with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22806

7 January 2021

Gene expression profiling and breast cancer care: what are the potential benefits and policy implications?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22806

7 January 2021

Chemokines, cytokines and their receptors in Hodgkin's lymphoma cell lines and tissues

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22806

7 January 2021

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22806

7 January 2021

HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22806

7 January 2021

Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22806

7 January 2021

Assessing the health of the nation. The predictive validity of a preference-based measure and self-rated health

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22806

7 January 2021

The cost of adjuvant chemotherapy in patients with early-stage breast carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22806

7 January 2021

Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22806

7 January 2021

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22806

7 January 2021

Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22806

7 January 2021

Adjuvant endocrine therapy in hormone receptor-positive postmenopausal breast cancer: evolution of NCCN, ASCO, and St Gallen recommendations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22806

7 January 2021

HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22806

7 January 2021

Concordance between central and local laboratory HER2 testing from a community-based clinical study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22806

7 January 2021

Identifiers

DOI

10.1002/CNCR.22806

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17592827%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

1 reference